Fairholme Capital, led by Bruce Berkowitz, holds 76.43% of its portfolio in St. Joe Company, a Northwest Florida land developer, reflecting strong conviction as the company posted its highest Q2 revenue in 20 years with significant margin expansions. Despite trimming St. Joe shares slightly, Fairholme added positions in Pfizer, Campbell Soup, and UPS, signaling a shift towards beaten-down, cash-generating sectors. While St. Joe shows promising growth and capital returns, its high concentration poses risks for typical investors. Following Fairholme's sector rotation into defensive stocks like Pfizer and UPS may be a safer entry point for retail investors.
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
Pfizer is considered a cautious Buy, trading near its intrinsic value with an expected 10% annual return mainly from its high dividend yield. However, the company faces significant challenges including a looming patent cliff, a stretched balance shee...
Galmed Pharmaceuticals announced preclinical results showing that combining Aramchol with Xtandi (enzalutamide) increased prostate cancer cell death by 3-4 times compared to Xtandi alone. Xtandi, a major prostate cancer drug with global sales of $8 b...
